Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Liabilities from Discontinued Operations (2022 - 2024)

Perspective Therapeutics' Liabilities from Discontinued Operations history spans 3 years, with the latest figure at 5070000.0 for Q1 2024.

  • For Q1 2024, Liabilities from Discontinued Operations changed N/A year-over-year to 5070000.0; the TTM value through Mar 2024 reached 5070000.0, changed N/A, while the annual FY2023 figure was 5072000.0, 1432.33% up from the prior year.
  • Liabilities from Discontinued Operations for Q1 2024 was 5070000.0 at Perspective Therapeutics, roughly flat from 5072000.0 in the prior quarter.
  • Across five years, Liabilities from Discontinued Operations topped out at 5072000.0 in Q4 2023 and bottomed at 331000.0 in Q4 2022.
  • The 3-year median for Liabilities from Discontinued Operations is 5070000.0 (2024), against an average of 3491000.0.
  • The largest YoY upside for Liabilities from Discontinued Operations was 1432.33% in 2023 against a maximum downside of 1432.33% in 2023.
  • A 3-year view of Liabilities from Discontinued Operations shows it stood at 331000.0 in 2022, then surged by 1432.33% to 5072000.0 in 2023, then decreased by 0.04% to 5070000.0 in 2024.
  • Per Business Quant, the three most recent readings for CATX's Liabilities from Discontinued Operations are 5070000.0 (Q1 2024), 5072000.0 (Q4 2023), and 331000.0 (Q4 2022).